NLRP3 and neoplasm: As applying an NLRP3 inhibitor suppressed glioblastoma angiogenesis and overexpressed KDELC2 could reverse the inhibition of tumor vascularity, we demonstrated that KDELC2 played a critical role in enhancing or regulating glioblastoma angiogenesis via ROS-induced NLRP3 activation.